CHICAGO, Dec. 16 A new application developed by American Imaging ManagementŪ (AIM) to manage the clinical review of specialty pharmaceuticals has increased health plan staff productivity and the number of drugs reviewed while reducing costs.
AIM, a leading diagnostic imaging benefit management and technology company with health plan clients representing over 35 million consumers and an operating subsidiary of WellPoint, Inc. (NYSE: WLP), adapted the successful clinical and technology platform used by the company to manage diagnostic imaging to meet the growing challenge of specialty pharmaceuticals, which include drugs that are typically high-cost oral and injectable medications used in treating complex, chronic diseases.
The adaptable platform allows a health plan to either implement the application within its own call center to enhance existing processes or to contract management of the program with AIM.
"Specialty pharmaceuticals are the fastest growing component of drug spend. The twenty percent annual growth rate for these drugs is similar to what was seen in outpatient diagnostic imaging prior to radiology benefit management," said Brandon Cady, president of AIM. "Whether a program is managed by a health plan or by AIM, our application is an effective and efficient clinical solution that delivers immediate and significant results."
Using the company's well-established clinical and technology platform as a starting point, AIM developed a clinical review application for specialty pharmaceuticals. The application utilizes clinical algorithms similar in form to the ones used by AIM to review diagnostic imaging, adapted for the unique aspects of these drugs.
"We knew that maintaining the form and function of our clinical algorithms was critical to creating a system that could effectively and efficiently review orders for these drugs," said Thomas Weisman, M.D., chief medical officer of AIM. "However, we also recognized that there were unique clinical requirements -- such as knowing certain patient demographics, drug strength and dosage amounts -- that would require us to customize our existing system."
Working with an advisory group that included health plan medical and pharmacy experts, AIM's initial version of the application was completed and rolled out in partnership with WellPoint's affiliated health plans in December 2008.
"Due to rapidly growing costs, WellPoint's plans established a clinical review process of specialty pharmaceutical orders in 2006," said Anthony Nguyen, MD., senior vice president of care management at WellPoint. "However, our process was entirely paper-driven, resulting in administrative inefficiencies. It also limited the number of drugs we could review. We needed a better system and were excited to work with AIM given their success in diagnostic imaging management."
Since the initial program rollout, the number of WellPoint plans using the application has increased from 1 to 12 and the number of drugs available for review has grown from 45 to 75. The application has had a significant impact on WellPoint's specialty pharmaceutical review program.
"We are thrilled with the impact that AIM's program has had on our review program," said Nguyen. "The average cost to review a case has decreased by 40 percent and average turnaround time has decreased by 65 percent. We now have the ability to review up to 75 drugs with a consistency in clinical guidelines and processes that didn't exist before."
In addition to improving the clinical review process, AIM's program expands a health plan's ability to manage the overall delivery of specialty pharmaceuticals.
"Our program allows health plans to manage drugs that are delivered under both the medical benefit and the pharmacy benefit. Drugs delivered under the medical benefit are often excluded from pre-authorization programs between a pharmaceutical benefit manager (PBM) and a health plan," noted Brandon Cady. "Our program allows health plans to manage these drugs more comprehensively as opposed to having them fall through the cracks."
The program also allows health plans to gather valuable clinical information. "Having a centralized system to gather and analyze ordering information offers significant value on its own," said Thomas Weisman. "Health plans can identify what type of specialty drug protocols are being used in the community to support identification and dissemination of best practices."
AIM's program will continue to evolve with the 2010 addition of specialty pharmacy to AIM's ProviderPortalŪ application. AIM's ProviderPortalŪ has been widely adopted for diagnostic imaging, processing over 50 percent of the imaging orders received by the company. The enhancement will allow providers to obtain clinical review for specialty pharmaceuticals using the same easy-to-use web interface that is currently available for outpatient diagnostic imaging clinical review.
About American Imaging Management
American Imaging Management, Inc. ("AIM") is a leading company in the radiology benefit management industry. AIM promotes the appropriate use of diagnostic imaging through the application of widely accepted clinical guidelines delivered through an innovative platform of technologies and programs. AIM pioneered the use of web technology in diagnostic imaging management and has continually integrated service and technology to create a more effective and efficient clinical review process to support the physician-patient relationship. Through a commitment to delivering excellence in clinical content, service, innovation and operational performance, AIM has developed a national client base of health plans, and currently provides management services to over 35 million health plan members. AIM is an operating subsidiary of WellPoint, Inc. (NYSE: WLP). For more information on AIM, please visit http://www.americanimaging.net.
WellPoint works to simplify the connection between Health, Care and Value. We help to improve the health of our communities, deliver better care to members, and provide greater value to our customers and shareholders. WellPoint is the nation's largest health benefits company, with nearly 34 million members in its affiliated health plans. As an independent licensee of the Blue Cross and Blue Shield Association, WellPoint serves members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as the Blue Cross Blue Shield licensee in 10 New York City metropolitan and surrounding counties and as the Blue Cross or Blue Cross Blue Shield licensee in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), Wisconsin; and through UniCare. Additional information about WellPoint is available at www.wellpoint.com.
SOURCE American Imaging Management